Trial Profile
A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors UCB
- 05 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2014 Planned End Date changed from 1 Jul 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
- 15 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.